MariTide Monthly Dosing MARITIME Phase III — PatSnap Eureka
MariTide Monthly Dosing & MARITIME Phase III: Amgen's GIP Antagonist/GLP-1 Agonist Race
Amgen's MariTide (AMG 133) combines GIPR antagonism with GLP-1R agonism in a monthly-dosed bispecific antibody-peptide conjugate — advancing into the MARITIME Phase III program in obesity and cardiovascular disease. Explore the patent signals, mechanistic rationale, and competitive landscape with PatSnap Eureka.
MARITIME Competitive Landscape
Three mechanistic approaches targeting the incretin axis in obesity & CVD
How MariTide Combines GIPR Antagonism with GLP-1R Agonism
MariTide (AMG 133) is a bispecific antibody-peptide conjugate in which an anti-GIPR monoclonal antibody (IgG2 framework) is site-specifically conjugated to one or more GLP-1 receptor agonist peptides. The antibody arm blocks GIPR signaling while the covalently attached GLP-1 peptide simultaneously activates GLP-1R — a dual-action design retrieved across Amgen's foundational patent analytics dataset.
The mechanistic hypothesis underlying GIPR antagonism is that endogenous GIP may attenuate the anorectic effects of GLP-1 via counter-regulatory signaling. By blocking GIPR, MariTide aims to disinhibit GLP-1R-driven weight loss. GIPR is expressed in hypothalamic nuclei relevant to energy balance — including the arcuate nucleus and ventromedial hypothalamus — and its antagonism in rodent models reduces fat mass and food intake beyond GLP-1R agonism alone.
This mechanistic approach stands in direct contrast to tirzepatide's dual GIP/GLP-1 receptor agonism. As documented by published clinical literature, both approaches produce meaningful weight loss in humans, but the human translational data from MARITIME will be the critical dataset resolving whether antagonism or agonism of GIPR produces superior cardiometabolic outcomes. The life sciences innovation intelligence landscape places this as one of the most consequential unresolved mechanistic questions in obesity pharmacology.
Key downstream signaling nodes implicated in retrieved mechanistic literature include the cAMP/PKA pathway, hypothalamic POMC/AgRP neurons, and adipose triglyceride lipase (ATGL) — all relevant to the adipose tissue lipolysis and hypothalamic satiety circuits that MariTide's dual mechanism targets.
Patent Filing Landscape & Cardiovascular Evidence Benchmarks
Key quantitative signals from Amgen's IP portfolio and the clinical evidence bar set by approved incretin-axis therapies — sourced from PatSnap Eureka patent and literature analysis.
Amgen MariTide Platform: PCT Filing Timeline (2019–2022)
Three foundational patent families filed between 2019 and 2022 covering the anti-GIPR antibody/GLP-1 peptide conjugate architecture — coinciding with MariTide's preclinical-to-clinical transition.
MARITIME CVD Benchmark: SELECT Trial MACE Reduction
Semaglutide's SELECT trial established a 20% MACE risk reduction in obese non-diabetic patients with established CVD — the evidentiary bar MARITIME must replicate or exceed for a CVD label claim.
Three Mechanistic Approaches Competing in the Incretin-Axis Race
Retrieved patent and literature signals identify three distinct pharmacological strategies targeting the GIP/GLP-1 axis in obesity and cardiometabolic disease — each with distinct IP, clinical, and regulatory profiles.
GIPR Antagonist + GLP-1R Agonist Bispecific Conjugate
MariTide (AMG 133) is an IgG2 antibody site-specifically conjugated to GLP-1 peptide analogues. The antibody arm fully antagonizes GIPR while the peptide arm activates GLP-1R. The IgG2 Fc scaffold enables FcRn-mediated recycling for once-monthly subcutaneous dosing — a pharmacokinetic differentiator from weekly injectables. Three PCT patent families (WO2020028334A1, WO2021076908A1, WO2022046772A1) cover this architecture, filed 2019–2022. MARITIME Phase III encompasses obesity and CVD endpoints.
Phase III · Monthly dosing · MARITIMEDual GIP/GLP-1 Receptor Agonist
Tirzepatide simultaneously activates both GIPR and GLP-1R — the opposite GIPR pharmacology to MariTide. Retrieved literature (Frías JP et al., NEJM 2021; Nature Medicine 2022) documents tirzepatide's superiority over semaglutide in glycemic control and body weight reduction in type 2 diabetes. As an FDA-approved agent, tirzepatide sets the clinical weight loss benchmark (~15–20% body weight reduction) that MARITIME must match or exceed. The mechanistic controversy — agonism vs. antagonism of GIPR — remains the field's most consequential unresolved question.
FDA Approved · Weekly dosing · SURPASS/SURMOUNTGLP-1R Agonist Monotherapy — The CVOT Reference Standard
Semaglutide (Ozempic/Wegovy) is a GLP-1R agonist without GIPR activity, establishing the cardiovascular outcomes evidence base via the SELECT trial (Lincoff AM et al., NEJM 2023): a 20% MACE risk reduction in adults with obesity and established CVD without diabetes. This SELECT CVOT result defines the regulatory bar for any new agent seeking a cardiovascular label claim. MARITIME's CVD arm is designed against this benchmark — MariTide must demonstrate at least comparable MACE reduction, with the GIPR antagonist layer potentially providing additive cardioprotection.
FDA Approved · SELECT CVOT · 20% MACE reductionGIPR Antagonism as a Broader Antibody-Peptide Conjugate Platform
Retrieved Amgen patents (2020–2022) claim not only AMG 133 itself but a broader platform of anti-GIPR antibody conjugates with varying GLP-1 peptide formats, linker chemistries, and Fc engineering variants. This signals potential pipeline expansion beyond MariTide for additional indications or dosing formats. Retrieved academic literature also highlights mechanistic overlap with NASH/MASLD (hepatic fat reduction, insulin sensitization), suggesting possible label expansion signals beyond obesity and CVD — though no MARITIME NASH arm was identified in retrieved results. Materials and conjugate chemistry innovation in this space is accelerating.
Platform IP · NASH signal · Linker chemistryAmgen's Patent Position: Claim Coverage & Competitive Clearance
Retrieved patent data reveals Amgen's concentrated IP estate around the GIPR antagonist/GLP-1R agonist platform — with strategic implications for competitors and biosimilar entrants.
Need claim-level clearance analysis for GIPR-targeting programs?
PatSnap Eureka maps the full incretin-axis IP landscape with AI-powered patent analytics
MARITIME Phase III: Binary Catalysts & Investable Risks
Retrieved patent and literature signals translate into five strategic implications for the MARITIME readout and the broader GIPR antagonist/GLP-1R agonist competitive landscape.
IP Position Is Strong but Narrow
In this dataset, Amgen holds concentrated patent coverage over the anti-GIPR antibody/GLP-1 peptide conjugate architecture (WO2020028334A1, WO2021076908A1, WO2022046772A1). Competitors seeking to enter the GIPR antagonist space will face claim-level clearance challenges, particularly for Fc-conjugated formats with monthly dosing intervals.
MARITIME Readout Is a Binary Catalyst
No Phase III efficacy data was found in retrieved results; the MARITIME program outcome will determine whether GIPR antagonism can match or exceed the ~15–20% body weight reduction achieved by tirzepatide and semaglutide in pivotal trials. Retrieved literature establishes these as the competitive benchmarks.
CVD Label Claim Requires MACE Data
Retrieved SELECT trial results demonstrate that GLP-1R agonism alone produces a statistically significant 20% MACE reduction in obese non-diabetic patients. For MariTide to secure a CVD indication, MARITIME must replicate this signal with the added GIPR antagonist layer — a higher regulatory bar than weight loss alone.
Monthly Dosing Is a Market Access Lever
Retrieved patent data emphasizes once-monthly subcutaneous dosing, which could be decisive for payer formulary positioning and patient adherence in chronic obesity therapy, especially if weight loss magnitude is comparable to weekly agents. Patent language specifying monthly dosing regimens appears as method-of-treatment claims.
What Retrieved Evidence Says About MARITIME Phase III Readiness
Retrieved results confirm that Amgen's Phase I/II dose-escalation for MariTide has been completed. Patent filings reference human dose-finding studies and describe pharmacokinetic parameters consistent with monthly dosing in adult subjects with obesity. Patent language references "therapeutically effective amounts" calibrated to clinical dosing intervals — consistent with an IND-enabling package that has progressed to Phase III initiation.
The clinical translation pathway for MariTide is supported by preclinical NHP data: retrieved patent language references cynomolgus monkey studies demonstrating weight loss and metabolic improvements with anti-GIPR/GLP-1 conjugates. This cross-species validation is critical for the toxicology package underpinning the MARITIME Phase III design.
Critically, no Phase III efficacy data was identified in the retrieved dataset — consistent with the MARITIME program being ongoing at the time of this analysis. The ClinicalTrials.gov registry and future publications will be the primary sources for interim or final readout data. The patent analytics record, however, provides a rich window into the molecular architecture and IP strategy that will define MariTide's commercial positioning post-readout.
GIPR expression in bone and cardiovascular tissue — identified in retrieved results — raises questions about long-term safety monitoring in chronic dosing, a consideration relevant to MARITIME Phase III safety endpoint design and post-marketing commitment planning. The FDA and EMA will likely require long-duration bone density and cardiac monitoring data for a chronic obesity indication.
MariTide & MARITIME Phase III — key questions answered
MariTide (AMG 133) is a bispecific antibody-peptide conjugate that combines gastric inhibitory polypeptide receptor (GIPR) antagonism with GLP-1 receptor agonism, engineered for monthly subcutaneous administration. Tirzepatide, by contrast, is a dual GIP/GLP-1 receptor agonist that activates both receptors simultaneously. Amgen's antagonist approach hypothesizes that blocking GIPR disinhibits GLP-1R-driven weight loss, whereas tirzepatide activates GIPR. Both approaches are currently being tested in parallel clinical programs.
MARITIME is Amgen's Phase III clinical program for MariTide (AMG 133), encompassing obesity (primary weight loss endpoint) and cardiovascular disease (MACE reduction). No Phase III efficacy data was found in retrieved results at the time of this analysis, indicating the trial is ongoing or results are not yet published in patent or literature records accessible at the time of search.
MariTide uses an IgG2 Fc antibody scaffold that enables FcRn-mediated recycling, prolonging serum half-life sufficiently for once-monthly subcutaneous dosing. Retrieved Amgen patent filings (WO2020028334A1, WO2021076908A1, WO2022046772A1) reveal specific engineering of the IgG2 Fc region and site-specific conjugation of GLP-1 peptides, enabling a defined stoichiometry and reduced heterogeneity — a significant clinical convenience advantage over weekly injectables such as semaglutide and tirzepatide.
The SELECT trial with semaglutide demonstrated a 20% MACE risk reduction in adults with obesity and established cardiovascular disease, without diabetes. For MariTide to secure a CVD indication, MARITIME must replicate this signal with the added GIPR antagonist layer — a higher regulatory bar than weight loss alone.
The mechanistic hypothesis is that endogenous GIP may attenuate the anorectic effects of GLP-1 via counter-regulatory signaling, and that blocking GIPR disinhibits GLP-1R-driven weight loss. GIPR is expressed in hypothalamic nuclei relevant to energy balance (arcuate nucleus, ventromedial hypothalamus), and its antagonism in rodent models reduces fat mass and food intake beyond GLP-1R agonism alone.
In this dataset, Amgen holds concentrated patent coverage over the anti-GIPR antibody/GLP-1 peptide conjugate architecture across three foundational PCT patent families: WO2020028334A1 (2020), WO2021076908A1 (2021), and WO2022046772A1 (2022). Competitors seeking to enter the GIPR antagonist space will face claim-level clearance challenges, particularly for Fc-conjugated formats with monthly dosing intervals.
Still have questions about MariTide or the GIPR antagonist landscape? Let PatSnap Eureka answer them.
Ask PatSnap Eureka About MariTideGet Ahead of the MARITIME Readout with AI-Powered Drug Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track cardiometabolic drug pipelines, map GIPR antagonist IP, and benchmark incretin-axis clinical programs.
References
- Anti-GIPR antibody and GLP-1 conjugates and uses thereof — Amgen Inc., 2020, WO (PCT) [Patent]
- GIPR antagonist antibodies and GLP-1 receptor agonist conjugates and uses thereof — Amgen Inc., 2021, WO (PCT) [Patent]
- Peptide-antibody conjugates for use in treating obesity — Amgen Inc., 2022, WO (PCT) [Patent]
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes — Frías JP et al., 2021, New England Journal of Medicine [Paper]
- Dual GIP and GLP-1 receptor agonist treatment improves metabolic outcomes in type 2 diabetes — Frías JP et al., 2022, Nature Medicine [Paper]
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial) — Lincoff AM et al. (SELECT Trial Investigators), 2023, New England Journal of Medicine [Paper]
- GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach — Müller TD et al., 2022, Molecular Metabolism [Paper]
- ClinicalTrials.gov — MARITIME Phase III trial registry (Amgen)
- U.S. Food and Drug Administration (FDA) — Obesity and cardiovascular drug approval guidance
- European Medicines Agency (EMA) — Cardiovascular outcomes trial guidance for obesity therapeutics
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.